NSCLC
Novartis lung cancer combo receives FDA approval
June 23, 2017Medical Communications, Sales and Marketing NSCLC, Novartis
Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist …
Pfizer drug beats AZ rival in halting lung cancer
June 6, 2017Manufacturing and Production, Research and Development NSCLC, Pfizer
New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression …
FDA approves Novartis’ Zykadia as first-line lung cancer treatment
May 30, 2017Manufacturing and Production, Sales and Marketing FDA, NSCLC, Novartis
The FDA has announced it has approved Novartis’ Zykadia (ceritinib) as a first line treatment in the expanded indication of …
AZ’s Tagrisso continues successes with EU approval
April 26, 2017Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso
More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …
Novartis combo expands into lung cancer with EU approval
April 4, 2017Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist
Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
NICE knocks back MSD’s Keytruda for lung cancer indication
February 28, 2017Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda
MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …
Novartis’ drug doubly effective as chemotherapy for treating lung cancer
December 8, 2016NSCLC, Novartis, chemotherapy
Novartis have released that its drug, Zykadia, in Phase III trials, was twice as effective at slowing progression in advanced …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment
October 21, 2016Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer
Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …
Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine
March 16, 2016Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech
Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …
FDA approves Pfizer sNDA for Xalkori
March 14, 2016Research and Development, Sales and Marketing Cancer, EMA, NSCLC, Pfizer, Xalkori (crizotinib)
The US FDA has approved Pfizer’s supplemental new drug application (sNDA) for its kinase inhibitor Xalkori in treating patients with …
AstraZeneca’s Tagrisso gets EU lung cancer sign-off
February 4, 2016Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib
The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …
Pfizer lung cancer treatment gets expanded EU approval
December 1, 2015Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer
Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
Lilly cancer drug gets US approval
November 26, 2015NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology
Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …
Latest content
FibroFind appoints Lee Borthwick as CEO
